Irbesartan Jubilant

Irbesartan, the active ingredient in Irbesartan Jubilant, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It selectively lowers elevated blood pressure and is indicated for the treatment of hypertension in adult patients.

GNH USA supplies Irbesartan Jubilant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Clients benefit from reliable logistics and comprehensive documentation for import clearance.

Irbesartan acts on the renin‑angiotensin‑aldosterone system to control high blood pressure and related renal conditions.

Hypertension: reduces systolic and diastolic blood pressure, lowering cardiovascular risk. Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. Proteinuria associated with chronic kidney disease: decreases urinary protein excretion, supporting renal protection.

Irbesartan may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Upper respiratory tract infection

Serious or Rare Side Effects: - Angioedema - Hyperkalemia - Acute renal failure

When prescribing Irbesartan, clinicians should consider several safety measures.

Monitor blood pressure: adjust therapy based on regular measurements. Assess renal function: check serum creatinine and eGFR before initiation and periodically. Check electrolytes: especially potassium levels to detect hyperkalemia. Avoid use in patients with severe hepatic impairment: limited data available. Pregnancy: drug is contraindicated in the second and third trimesters due to fetal toxicity. Store at ambient temperature: keep below 25 °C, protect from moisture and light in original container.

Irbesartan can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Potassium‑sparing diuretics: may cause dangerous hyperkalemia. - ACE inhibitors or other ARBs: additive blood‑pressure lowering and renal effects. - Aliskiren in diabetic patients: increased risk of renal impairment.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and impair renal function. - Lithium: may increase serum lithium concentrations. - Cyclosporine or tacrolimus: may raise irbesartan plasma levels.